Skip to Content
Merck
All Photos(1)

Key Documents

V3003

Sigma-Aldrich

Monoclonal Anti-Vascular Endothelial Growth Factor Receptor-2 (KDR) antibody produced in mouse

clone 260.4, KDR-2, ascites fluid

Synonym(s):

Monoclonal Anti-Vascular Endothelial Growth Factor Receptor-2 antibody produced in mouse, Anti-KDR, Anti-VEGFR-2

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
51111800
NACRES:
NA.41

biological source

mouse

conjugate

unconjugated

antibody form

ascites fluid

antibody product type

primary antibodies

clone

260.4, KDR-2, monoclonal

contains

15 mM sodium azide

species reactivity

human

technique(s)

immunohistochemistry (frozen sections): suitable
indirect ELISA: suitable
western blot: 1:500 using insect cell culture supernatant expressing human extracellular recombinant VEGFR or VEGF Receptor-2 (KDR, FLK-1)/FC Chimera human, recombinant

isotype

IgG1

UniProt accession no.

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... KDR(3791)

Looking for similar products? Visit Product Comparison Guide

General description

Monoclonal Anti-Vascular Endothelial Growth Factor Receptor-2 (mouse IgG1 isotype) is derived from the KDR-2 hybridoma produced by the fusion of mouse myeloma cells and splenocytes from an immunized mouse. Vascular endothelial growth factor receptor 2 (VEGFR2) is a type V receptor tyrosine kinase, also known as kinase insert domain receptor (KDR) or fetal liver kinase 1 (Flk-1). It a glycosylated protein with an immunoglobulin (Ig)-like domains, a transmembrane domain and a tyrosine kinase domain. The KDR gene is mapped to human chromosome 4q12 and is widely expressed in all vessel-derived endothelial cells and hematopoietic stem cells.

Specificity

Reacts specifically with human VEGF receptor-2. This clone has also been termed 260.4. It does not recognize Flt1 (VEGFR-1), Flt4 (VEGFR-3), or platelet-derived growth factor receptor (PDGF-R).

Immunogen

purified recombinant human extracellular VEGF receptor-2 (KDR).

Application

Monoclonal Anti-Vascular Endothelial Growth Factor Receptor-2 (KDR) antibody produced in mouse has been used in:
  • immunofluorescence
  • immunohistochemistry
  • immunoblotting
  • enzyme-linked immunosorbent assay(ELISA)

Biochem/physiol Actions

Vascular Endothelial Growth Factor Receptor-2 (VEGF R2) have high affinity for vascular endothelial growth factor-A (VEGF-A), hence facilitates most of the endothelial growth and survival signals from VEGF-A. It also plays a pivotal role in vascular development, vascular permeability, embryonic hematopoiesis and regulation of angiogenesis.
Vascular endothelial growth factor receptor 2 (VEGFR2) or kinase insert domain receptor (KDR) is a VEGF receptor, which stimulates its mitogenic activity. It is crucial for vascular endothelial cell development. VEGFR2 expression is elevated in invasive breast cancer, hemangiomas and angiosarcomas. KDR expressing cells show striking changes in cell morphology, actin reorganization and membrane ruffling, chemotaxis, and mitogenicity in response to VEGF. Antibodies that react specifically with the VEGF receptor are useful for the study of the specific differential tissue expression and intracellular localization of the receptor in normal and neoplastic tissue.

Target description

The KDR receptor (VEGFRa), defining marker of hematopoietic stem cells (HSCs), distinguishes pluripotent HSCs from lineage-committed progenitor HSCs.

Physical form

The product is provided as ascites fluid with 15 mM sodium azide as a preservative.

Storage and Stability

For continuous use, store at 2-8 °C for up to one month. For extended storage freeze in working aliquots. Repeated freezing and thawing, or storage in "frost-free" freezers,is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

J M Ou et al.
European journal of histochemistry : EJH, 58(1), 2263-2263 (2014-04-08)
Angiogenesis is a process of development and growth of new capillary blood vessels from pre-existing vessels. Angiogenic growth factors play important roles in the development and maintenance of some malignancies, of which vascular endothelial growth factor (VEGF)/VEGFR2 interactions are involved
Masabumi Shibuya
Cancer science, 94(9), 751-756 (2003-09-12)
Vascular endothelial growth factor receptor-2 (VEGFR-2/KDR/Flk-1) is a high-affinity receptor for vascular endothelial growth factor-A (VEGF-A), and mediates most of the endothelial growth and survival signals from VEGF-A. VEGFR-2 has a typical tyrosine kinase receptor structure with seven immunoglobulin (Ig)-like
S Ogawa et al.
The Journal of biological chemistry, 273(47), 31273-31282 (1998-11-13)
Vascular endothelial growth factor (VEGF) mediates endothelial cell proliferation, angiogenesis, and vascular permeability via the endothelial cell receptors, KDR/Flk-1 and Flt-1. Recently, a gene encoding a polypeptide with about 25% amino acid identity to mammalian VEGF was identified in the
Irawan Satriotomo et al.
Experimental neurology, 237(1), 103-115 (2012-06-19)
Acute intermittent hypoxia (AIH) initiates plasticity in respiratory motor control, including phrenic long term facilitation (pLTF). Since pLTF is enhanced by preconditioning with repetitive exposure to AIH (rAIH), we hypothesized that a rAIH protocol consisting of 3 AIH exposures per
Nikola Holtkamp et al.
Neuro-oncology, 9(3), 291-297 (2007-05-17)
A subset of glioblastomas (GBMs) carry gene amplifications on chromosomal segment 4q12. To characterize this amplicon in detail, we analyzed a set of 100 samples consisting of 65 GBMs, 10 WHO grade III astrocytomas, 12 oligodendrogliomas, and 13 glioma cell

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service